US-based biopharmaceutical company Constellation Pharmaceuticals closed a $55m round of funding on Wednesday backed by SR One, the corporate venturing arm of pharmaceutical firm GlaxoSmithKline.
Private equity firm Topspin Partners co-led the round with undisclosed investors, while Third Rock Ventures, Column Group, Venrock and unnamed funds also contributed capital.
Founded in 2008, Constellation’s treatments are based on the study of epigenetics, the field of genetics that seeks to understand changes in genes which are not caused by changes in the…